News
PHAR
10.84
0.00%
0.00
Weekly Report: what happened at PHAR last week (0318-0322)?
Weekly Report · 4d ago
Weekly Report: what happened at PHAR last week (0311-0315)?
Weekly Report · 03/18 10:31
Pharming Group’s Strong Performance and Growth Prospects Justify Buy Rating
Analyst Christian Glennie maintained a Buy rating on the stock and has a €2.05 price target. Glennie highlighted the unexpected 10% growth in revenue from Ruconest in 2023. The strong initial performance of the drug Joenja in the U.S. Market.
TipRanks · 03/18 09:05
Pharming reports Q4 results
Seeking Alpha · 03/15 19:36
Pharming Group Price Target Maintained With a $37.00/Share by HC Wainwright & Co.
Dow Jones · 03/14 16:45
Pharming Group’s Strong Financial Performance and Growth Potential Merit Buy Rating
TipRanks · 03/14 15:35
Earnings Scheduled For March 14, 2024
Pharming is projected to report earnings for its fourth quarter. Dick's Sporting Goods is expected to report quarterly earnings at $3.35 per share on revenue of $817.48 million. Other companies expected to release earnings before the bell include Hello Gr, Weibo and Build-A-Bear Workshop.
Benzinga · 03/14 09:52
Pharming Group Expects 2024 Total Revenue Of $280M-$295M
For 2024, the Company anticipates: Total revenues between US$280 million and US$295 million (14% to 20% growth) Progress towards regulatory approvals for leniolisib in key global markets. Continued focus on potential acquisitions and in-licensing of clinical stage opportunities in rare diseases.
Benzinga · 03/14 06:10
Pharming Q4 EPS $0.00 Up From $(0.02) YoY, Sales $81.20M Up From $54.62M YoY
Pharming (NASDAQ:PHAR) reported quarterly earnings of $0.00 per share. The company reported $81.20 million in sales this quarter. This is a 48.66 percent increase over sales of $54.62 million the same period last year.
Benzinga · 03/14 06:07
Pre-Market Earnings Report for March 14, 2024 : DG, DKS, BEKE, WB, GIII, CSIQ, MOMO, AUTL, PHAR, URGN, AVAH, BBW
NASDAQ · 03/13 20:00
Weekly Report: what happened at PHAR last week (0304-0308)?
Weekly Report · 03/11 10:29
Weekly Report: what happened at PHAR last week (0226-0301)?
Weekly Report · 03/04 10:31
Weekly Report: what happened at PHAR last week (0219-0223)?
Weekly Report · 02/26 10:39
Weekly Report: what happened at PHAR last week (0212-0216)?
Weekly Report · 02/19 10:41
EUROPE RESEARCH ROUNDUP-Heineken NV, Integrafin Holdings Plc, Kingfisher
Analysts revise their ratings and price targets on several European companies. Heineken NV, Integrafin Holdings Plc, Kingfisher and Neste Oyj among those. HSBC cuts target price on Heinekens NV to hold from buy. Morgan Stanley initiates coverage of Neste.
Reuters · 02/15 07:10
Weekly Report: what happened at PHAR last week (0205-0209)?
Weekly Report · 02/12 10:34
Weekly Report: what happened at PHAR last week (0129-0202)?
Weekly Report · 02/05 10:39
Weekly Report: what happened at PHAR last week (0122-0126)?
Weekly Report · 01/29 10:32
Weekly Report: what happened at PHAR last week (0115-0119)?
Weekly Report · 01/22 10:35
Weekly Report: what happened at PHAR last week (0108-0112)?
Weekly Report · 01/15 10:32
More
Webull provides a variety of real-time PHAR stock news. You can receive the latest news about Pharming Group N.V. through multiple platforms. This information may help you make smarter investment decisions.
About PHAR
Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.